Fondaparinux Sodium Is Not Metabolised in Mammalian Liver Fractions and Does Not Inhibit Cytochrome P450-Mediated Metabolism of Concomitant Drugs
- 1 January 2002
- journal article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 41 (Supplement) , 19-26
- https://doi.org/10.2165/00003088-200241002-00003
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Absence of Interaction of Fondaparinux Sodium with Digoxin in Healthy VolunteersClinical Pharmacokinetics, 2002
- Absence of Interaction of Fondaparinux Sodium with Aspirin and Piroxicam in Healthy Male VolunteersClinical Pharmacokinetics, 2002
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture SurgeryNew England Journal of Medicine, 2001
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee SurgeryNew England Journal of Medicine, 2001
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip ReplacementNew England Journal of Medicine, 2001
- SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic AgentCardiovascular Drug Reviews, 1997
- New Antithrombotic Agents For The Prevention And Treatment Of Deep Vein ThrombosisPathophysiology of Haemostasis and Thrombosis, 1996
- Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicityToxicology Letters, 1994
- The role of individual human cytochrpmes P450 in drug metabolism and clinical responseTrends in Pharmacological Sciences, 1992
- Heparin Pharmacokinetics and PharmacodynamicsClinical Pharmacokinetics, 1992